Comparative Pharmacology
Head-to-head clinical analysis: LINZESS versus TRULANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINZESS versus TRULANCE.
LINZESS vs TRULANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.
Guanylate cyclase-C receptor agonist; increases intracellular cGMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.
72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.
3 mg orally once daily.
None Documented
None Documented
Terminal half-life is 6.6 hours (range 4 – 12 h) in healthy subjects; not prolonged in renal or hepatic impairment.
Terminal elimination half-life is approximately 16 hours, supporting once-daily dosing.
Primarily fecal (95%) as intact drug; renal excretion accounts for <1%.
Primarily excreted in feces as unchanged drug (approximately 60%) and as metabolites; renal excretion is minimal (<3%).
Category C
Category C
Guanylate Cyclase-C Agonist
Guanylate Cyclase-C Agonist